JPH04503069A - 高いイブプロフェン含有量を示す顆粒状物 - Google Patents
高いイブプロフェン含有量を示す顆粒状物Info
- Publication number
- JPH04503069A JPH04503069A JP2503127A JP50312790A JPH04503069A JP H04503069 A JPH04503069 A JP H04503069A JP 2503127 A JP2503127 A JP 2503127A JP 50312790 A JP50312790 A JP 50312790A JP H04503069 A JPH04503069 A JP H04503069A
- Authority
- JP
- Japan
- Prior art keywords
- binder
- ibuprofen
- composition
- granules
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.薬学的な、高い薬剤含有量のイブプロフェン顆粒状組成物であって、(a) 乾量基準でイブプロフェン約85乃至約99%、(b)乾量基準で薬学的に受容 可能なバインダー約0.9乃至約15.0%、(c)乾量基準でポリビニルヒロ リドン約0.1乃至5.0%、および(d)全量量の0.1乃至2.0%を占め る水分含量を含んで成るもの、ここにおいて、前記顆粒状物は凝集物の形状を成 すものとする。 2.前記バインダーが、澱粉、セルロース、および砂糖から成る群から選択され る請求項1による組成物。 3.前記バインダーがプレゼラチン化澱粉である請求項2による組成物。 4.前記バインダーがマイクロクリスタリン・セルロースである請求項2による 組成物。 5.前記ポリビニルヒロリドンが分子量平均値600,000ダルトン超過(K 値は90以上)を有する請求項1による組成物。 6.前記水分が全重量の約0.8乃至約1.8%を占める請求項1による組成物 。 7.前記ポリビニルヒロリドンが乾量基準で約0.5%である請求項1による組 成物。 8.前記イブプロフェンは乾量基準で約90%存在し、前記バインダーは乾量基 準で約9.5%存在し、そして前記ポリビニルビロリドンは乾量基準で約0.5 %存在する請求項1による組成物。 9.イブプロフェン/圧縮錠剤の投薬量範囲が100乃至1200mgに及ぶ錠 剤に直接圧縮するために有用である薬学的な顆粒状組成物であって、該組成物は (a)イブプロフェン、バインダー、およびポリビニルビロリドンを含有する請 求項1による顆粒、 (b)潤滑量における薬学的に受容可能な潤滑剤、(c)錠剤結合量における薬 学的に受容可能なバインダー、(d)崩壊量における薬学的に受容可能な崩壊剤 、および(e)場合により、水を含んで成る。 10.前記潤滑剤が、ステアリン酸、ステアリン酸カルシウム、ステアリン酸マ グネシウム、ステアリン酸ナトリウム、ステアリン酸亜鉛、ラウリル硫酸ナトリ ウム、ポリエチレングリコール、水素化植物油、およびタルクから成る群から選 択される請求項9による組成物。 11.(c)の前記バインダーが、ヒドロキシプロヒルメチルセルロース、ヒド ロキシプロヒルセルロース、カルボキシメチルセルロースから成る群から選択さ れる請求項9による組成物。 12.請求項9による組成物の直接圧縮によって調製される錠剤。 13.請求項1による顆粒状組成物を調製する方法であって、(a)前記イブプ ロフェンを前記バインダーの一部と共に充分にブレンドされるまで流動化させる 工程と、 (b)前記流動化されたイブプロフェンブレンドを、前記ポリビニルビロリドン および水中の前記バインダーの残部から成る分散液と共にスプレーする工程と、 (c)得られた顆粒を最大水分レベルである全量の2.0%に乾燥させる工程と を含んで構成される方法。 14.前記顆粒を均一な寸法に篩分けする工程を更に含んで成る請求項1による 方法。 15.前記イブプロフェンと共に流動化された前記バインダーが乾量基準で前記 組成物の約4.0乃至約6.0%であり、またバインダーの残部が乾量基準で約 3.5乃至約5.5%である請求項13による方法。 16.前記イブプロフェンと共に流動化された前記バインダーが乾量基準で前記 組成物の約4.5%であり、またバインダーの残部が乾量基準で約5.0%であ る請求項13による方法。 17.前記乾燥工程(c)が前記組成物の水分含量を水約0.8乃至約1.8重 量%に減少させる請求項13による方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US306,014 | 1989-02-02 | ||
US07/306,014 US4911921A (en) | 1989-02-02 | 1989-02-02 | High ibuprofen content granulations |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04503069A true JPH04503069A (ja) | 1992-06-04 |
JP2556623B2 JP2556623B2 (ja) | 1996-11-20 |
Family
ID=23183358
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2503127A Expired - Lifetime JP2556623B2 (ja) | 1989-02-02 | 1990-01-31 | 高いイブプロフェン含有量を示す顆粒状物 |
Country Status (10)
Country | Link |
---|---|
US (1) | US4911921A (ja) |
EP (1) | EP0456720B1 (ja) |
JP (1) | JP2556623B2 (ja) |
AT (1) | ATE124257T1 (ja) |
AU (1) | AU629913B2 (ja) |
CA (1) | CA2045680C (ja) |
DE (1) | DE69020541T2 (ja) |
DK (1) | DK0456720T3 (ja) |
ES (1) | ES2076358T3 (ja) |
WO (1) | WO1990008542A1 (ja) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5104648A (en) * | 1989-02-02 | 1992-04-14 | Mallinckrodt Specialty Chemicals Company | High ibuprofen content granulations |
US5087454A (en) * | 1990-07-30 | 1992-02-11 | American Home Products Corporation | Ibuprofen tablet |
GB9119052D0 (en) * | 1991-09-06 | 1991-10-23 | Boots Co Plc | Pharmaceutical compositions |
US5191114A (en) * | 1991-10-09 | 1993-03-02 | Sage Pharmaceuticals, Inc. | Process for enhancing the flow characteristics of ibuprofen |
US5310961A (en) * | 1993-07-02 | 1994-05-10 | Affinity Biotech, Inc. | Neomorphic ibuprofen |
US6348216B1 (en) * | 1996-06-10 | 2002-02-19 | Knoll Pharmaceutical Company | Ibuprofen and narcotic analgesic compositions |
US6361794B1 (en) | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
US5837292A (en) * | 1996-07-03 | 1998-11-17 | Yamanouchi Europe B.V. | Granulate for the preparation of fast-disintegrating and fast-dissolving compositions containing a high amount of drug |
FR2772617B1 (fr) * | 1997-12-19 | 2001-03-09 | Besins Iscovesco Lab | Comprime de progesterone et son procede de preparation |
IT1301966B1 (it) | 1998-07-30 | 2000-07-20 | Zambon Spa | Composizioni farmaceutiche ad attivita' analgesica |
US6251945B1 (en) | 1999-01-14 | 2001-06-26 | Knoll Aktiengesellschaft | Pharmaceutical mixture comprising a combination of a profen and other active compounds |
DE10003757A1 (de) * | 2000-01-28 | 2001-08-02 | Knoll Ag | Ibuprofen-Wirkstoffzubereitung |
GB0209265D0 (en) | 2002-04-23 | 2002-06-05 | Novartis Ag | Organic compounds |
EA006008B1 (ru) † | 2002-04-29 | 2005-08-25 | Эгиш Дьёдьсердьяр Рт. | Способ получения таблеток из фармацевтически активных веществ |
US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
JP2008505074A (ja) * | 2004-06-30 | 2008-02-21 | アルベマール・コーポレーシヨン | 高イブプロフェン含有量顆粒並びにそれらの製造および製薬学的薬用量形態中でのそれらの使用 |
EP1741712B1 (en) | 2004-07-30 | 2011-06-15 | Torrent Pharmaceuticals Ltd | amorphous form of nebivolol hydrochloride and its preparation |
AU2006250340C1 (en) | 2005-05-26 | 2014-06-12 | Sumitomo Pharma Co., Ltd. | Pharmaceutical composition |
CA2577760A1 (en) * | 2006-02-27 | 2007-08-27 | Tyco Healthcare Group Lp | Pressurized dip coating system |
US20080069889A1 (en) * | 2006-03-07 | 2008-03-20 | Cherukuri S R | Compressible resilient granules and formulations prepared therefrom |
US20070212417A1 (en) * | 2006-03-07 | 2007-09-13 | Cherukuri S R | Compressible resilient granules and formulations prepared therefrom |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3108046A (en) * | 1960-11-25 | 1963-10-22 | Smith Kline French Lab | Method of preparing high dosage sustained release tablet and product of this method |
US4209513A (en) * | 1974-02-14 | 1980-06-24 | Burroughs Wellcome Co. | Tablet formulation |
US4661521A (en) * | 1984-04-30 | 1987-04-28 | Mallinckrodt, Inc. | Direct tableting acetaminophen compositions |
US4609675A (en) * | 1984-08-17 | 1986-09-02 | The Upjohn Company | Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing |
US4753801A (en) * | 1985-10-25 | 1988-06-28 | Eli Lilly And Company | Sustained release tablets |
US4757090A (en) * | 1986-07-14 | 1988-07-12 | Mallinckrodt, Inc. | Direct tableting acetaminophen compositions |
US4806359A (en) * | 1987-04-22 | 1989-02-21 | Mcneilab, Inc. | Iburprofen sustained release matrix and process |
US4837031A (en) * | 1987-09-17 | 1989-06-06 | Mallinckrodt, Inc. | Compositions containing ibuprofen |
-
1989
- 1989-02-02 US US07/306,014 patent/US4911921A/en not_active Expired - Lifetime
-
1990
- 1990-01-31 EP EP90902888A patent/EP0456720B1/en not_active Expired - Lifetime
- 1990-01-31 CA CA002045680A patent/CA2045680C/en not_active Expired - Lifetime
- 1990-01-31 DK DK90902888.8T patent/DK0456720T3/da active
- 1990-01-31 JP JP2503127A patent/JP2556623B2/ja not_active Expired - Lifetime
- 1990-01-31 WO PCT/US1990/000564 patent/WO1990008542A1/en active IP Right Grant
- 1990-01-31 DE DE69020541T patent/DE69020541T2/de not_active Expired - Lifetime
- 1990-01-31 AU AU50369/90A patent/AU629913B2/en not_active Expired
- 1990-01-31 ES ES90902888T patent/ES2076358T3/es not_active Expired - Lifetime
- 1990-01-31 AT AT90902888T patent/ATE124257T1/de not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69020541D1 (de) | 1995-08-03 |
AU5036990A (en) | 1990-08-24 |
ES2076358T3 (es) | 1995-11-01 |
WO1990008542A1 (en) | 1990-08-09 |
EP0456720B1 (en) | 1995-06-28 |
JP2556623B2 (ja) | 1996-11-20 |
DE69020541T2 (de) | 1995-11-02 |
EP0456720A1 (en) | 1991-11-21 |
ATE124257T1 (de) | 1995-07-15 |
US4911921A (en) | 1990-03-27 |
CA2045680C (en) | 1997-01-14 |
DK0456720T3 (da) | 1995-08-14 |
CA2045680A1 (en) | 1990-08-03 |
AU629913B2 (en) | 1992-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5104648A (en) | High ibuprofen content granulations | |
JPH04503069A (ja) | 高いイブプロフェン含有量を示す顆粒状物 | |
EP0377658B1 (en) | A free-flowing granular composition containing ibuprofen and a method for its preparation | |
JP6092936B2 (ja) | 口腔内崩壊錠の製造方法 | |
US4609675A (en) | Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing | |
RU2563819C2 (ru) | Лекарственные формы цитрата железа (iii) | |
TW576741B (en) | Formulation of fast-dissolving efavirenz capsules or tablets using super-disintegrants | |
EP0305051B1 (en) | Orally sustained-release acetaminophen formulation and process to obtain it | |
TW541180B (en) | Hydrolyzed cellulose granulations for pharmaceuticals | |
US5955107A (en) | Pharmaceutical suspension tablet compositions | |
US4562024A (en) | Process for preparing granulate containing poorly compressible medicinally active matter | |
JPS63280021A (ja) | イブプロフェン除放性錠剤及びその製造方法 | |
JP2012001557A (ja) | 改善された急速崩壊性錠剤 | |
JPH07509479A (ja) | 長期間にわたって2段階で放出する形態を有する固体の薬剤投与形態およびその製造 | |
JPS60209518A (ja) | 貯蔵安定性を有し急速に崩壊する薬学的に活性な物質を含有する圧縮成形体及びその製造方法 | |
JPH06206833A (ja) | 薬剤学的薬剤 | |
JPS62120315A (ja) | 経口投与型徐放性錠剤の製造方法 | |
JPS63290818A (ja) | 高分子量ヒドロキシプロピルメチルセルロースを基剤にした徐放性錠剤 | |
US5234691A (en) | Sustained-release prepararation of basic medical agent hydrochloride | |
JP2003505402A (ja) | 低用量錠剤および調製方法 | |
MX2011000709A (es) | Granulos con alto contenido de ibuprofeno sodico, su preparacion y su uso en preparar formas de dosificacion solidas no efervescentes. | |
EP2671569B1 (en) | Stable pharmaceutical compositions with fast onset | |
EA015349B1 (ru) | Твёрдая разовая пероральная фармацевтическая дозированная форма саквинавирмезилата и способ её изготовления | |
JPH02282323A (ja) | 徐放性錠剤の製造方法 | |
WO2023182332A1 (ja) | 口腔内崩壊錠用の添加剤組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080905 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090905 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100905 Year of fee payment: 14 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100905 Year of fee payment: 14 |